KRISTEN STREETT: Open Payments
NPI 1710615174 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,671 in 153 payments from 22 companies in 2025. Trend: 2023 $776 · 2024 $1,874 · 2025 $3,671
Food & beverage: $3,671
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $583 |
| Janssen Biotech, Inc. | 19 | $535 |
| Madrigal Pharmaceuticals | 18 | $448 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $403 |
| GENZYME CORPORATION | 9 | $262 |
| Ipsen Biopharmaceuticals, Inc | 7 | $205 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $204 |
| PFIZER INC. | 9 | $170 |
| Gilead Sciences, Inc. | 6 | $123 |
| Aimmune Therapeutics, Inc. | 5 | $119 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, ENTYVIO, IQIRVO, XIFAXAN, CREON, RINVOQ.
Industry payments across MD — which companies pay providers there.
